FERMENTA
Fermenta Biotech Limited (fermenta) H1fy27: Consolidated Revenue INR 261.9 Crore; Down 7% Yoy
Fermenta Biotech Limited (FERMENTA) reports H1FY27 consolidated revenue of INR 261.9 crore, down 7% YoY.
Fermenta Biotech Limited (FERMENTA) has announced its consolidated financial results for the half year ended September 30, 2026 (H1FY27). The company reported consolidated revenue of INR 261.9 crore, a 7% year-on-year decline. The EBITDA and profit after tax for the period were INR 45.6 crore and INR 18.9 crore respectively, down 34% and 52% year-on-year.
Revenue Breakdown
The revenue for the period was primarily driven by the Human Nutrition segment, which now accounts for close to two-thirds of the total revenue. The Vitamin D3 – Human Nutrition business saw a 2% growth despite a 13% year-on-year decline in volumes. The Vitamin D3 – Animal Nutrition segment experienced a significant drop, with volumes down 31% and average realization down 35% year-on-year.
Geographical Revenue Shift
India has emerged as the largest market for FERMENTA, contributing 51% of the consolidated revenue in H1FY27, up from 40% a year earlier. This shift underscores the company’s strategic focus on steadier markets while navigating the price cycle in animal nutrition.
Forward-Looking Statements
Prashant Nagre, Managing Director of Fermenta Biotech Limited, emphasized the company’s balanced approach, highlighting the FSSAI approval for VITADEE Green® and the expected readiness of Calcifediol by the end of FY27. He also noted the benefits of the company’s listing on the National Stock Exchange (NSE), which has broadened investor access.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Fermenta Biotech Limited
Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.
FERMENTA
Fermenta Biotech Limited (fermenta) Q1fy27: Consolidated Revenue INR 126.2 Crore; Flat Qoq and Down
Fermenta Biotech Limited (FERMENTA) announced consolidated revenue of INR 126.2 crore for Q1FY27, flat QoQ and down 13% YoY.
Fermenta Biotech Limited (FERMENTA) announced consolidated revenue of INR 126.2 crore for the first quarter of FY27, flat on a quarter and down 13% year-on-year. The company’s EBITDA, excluding real estate, was INR 22.3 crore, down 37% YoY and 10% QoQ. Despite the flat quarter-on-quarter performance, the company saw a 18% increase in human nutrition volumes. India’s contribution to consolidated revenue rose to 47% from 35% a year earlier.
Financial Highlights
The consolidated revenue for Q1FY27, including real estate, was INR 126.2 crore, down 13% YoY and flat QoQ. EBITDA was INR 22.4 crore, down 39% YoY and 11% QoQ. Profit after tax was INR 9.5 crore, down 56% YoY and 49% QoQ. The decline in profit after tax is attributed to three identifiable items in the April–June 2025 base quarter rather than the core business operations.
Segment Performance
The human nutrition segment revenue was INR 76.5 crore, maintaining its share at 61% of consolidated revenue. The animal nutrition segment saw a 52% QoQ decline and a 20% YoY decrease. Other segments like Other APIs and Intermediates and Green Chemistry Solutions/Enzymes showed growth, with revenues of INR 11.6 crore and INR 2.3 crore respectively.
Prashant Nagre, Managing Director, commented on the results, stating, ‘This was a quarter of building rather than harvesting. The year-on-year arithmetic sits against an exceptionally strong April–June 2025 base quarter.’ The company plans to build on its public awareness campaign on Vitamin D deficiency and leverage the FSSAI approval for VITADEE Green® to tap into India’s large vegetarian consumer base.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Fermenta Biotech Limited
Fermenta Biotech Limited. Here’s a quick read on where the business and the stock stand today.
Fermenta gains 91.5% over three months and trades near its 52-week highs. Revenue grows at only 0.0% and profits at 0.0% CAGR. In effect, the business treads water. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI hits 73, a level that signals the stock runs hot. Notably, buyers drove volume on 18 recent sessions — though at these levels, some profit-taking is normal. The stock rises 91.5% in three months. Yet revenue grows at only 0.0% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Fermenta Biotech Limited.
FERMENTA
Fermenta Biotech Lists on India’s National Stock Exchange (fermenta)
Fermenta Biotech Limited (FERMENTA) lists on India’s National Stock Exchange, enhancing accessibility and participation.
Fermenta Biotech Limited (FERMENTA) has successfully listed its equity shares on the National Stock Exchange of India Limited (NSE). Effective August 4, 2026, the company’s shares are now admitted to dealings on the NSE under the symbol FERMENTA and ISIN INE225B01021. This milestone marks a significant step in Fermenta’s 75-year journey, providing access to shareholders and market participants across both major Indian stock exchanges.
Dual Listing Advantage
The dual listing on the NSE and the Bombay Stock Exchange (BSE) under the code 506414 is expected to increase accessibility and participation for a wider community of investors. Prashant Nagre, Managing Director of Fermenta Biotech, emphasized that this listing enables broader participation, improved visibility, and more efficient price discovery.
Company’s Growth and Commitment
Founded in 1951 and listed on the BSE since 1977, Fermenta Biotech has grown from its pharmaceutical and biotechnology foundations into a globally recognized manufacturer. The company serves customers in more than 60 countries with its portfolio of premium nutritional ingredients, green chemistry, APIs, and customized food premixes. Nagre highlighted that the NSE listing reflects the company’s growth, expanding global customer base, and widening investor interest.
The listing ceremony was held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex, attended by representatives from NSE, Fermenta’s Board, and senior leadership team. This event commemorates Fermenta’s milestone year, celebrating 75 years of the company and nearly five decades as a publicly listed enterprise.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Fermenta Biotech Limited
Fermenta Biotech Limited. Here’s a quick read on where the business and the stock stand today.
Fermenta gains 81.6% over three months and trades near its 52-week highs. Revenue grows at only 0.0% and profits at 0.0% CAGR. In effect, the business treads water. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI hits 77, a level that signals the stock runs hot. Notably, buyers drove volume on 18 recent sessions — though at these levels, some profit-taking is normal. The stock rises 81.6% in three months. Yet revenue grows at only 0.0% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Fermenta Biotech Limited.
-
AKUMS3 days agoAkums Drugs and Pharmaceuticals Limited (akums) Q2 FY27: Revenue Up 32%, Ebitda and PAT Surge
-
Information Technology Services3 days agoOrient Technologies Limited (orienttech) Q2 FY27: Strong Profitability on Higher Managed Services Contribution
-
Consumer Cyclical3 days agoTbo Tek Limited (tbotek) Q2 FY27: Revenue Up 53%, Adj. Ebitda at ₹152 Crores
-
Industrials3 days agoAmara Raja Energy & Mobility Limited (are&m) Q2 FY27: Revenue Up 13%
-
Auto Parts3 days agoJay Bharat Maruti Limited Q2 FY’27 Results: PAT Up 72.59%, Revenue Grows 41.97%
-
Apparel Retail3 days agoArvind Fashions Limited Announces Highest Ever Revenue and Ebitda, Delivers Revenue Growth of 10.0% and Ebitda Growth of 15.5%
-
Basic Materials3 days agoJk Paper Limited (jkpaper) Q2 FY26: Consolidated Turnover Up 11%, PAT Rises 36%
-
Consumer Cyclical3 days agoSheela Foam Limited Q2 & H1 FY27 Results: Revenue Surpasses ₹1,000 Cr, PAT Up 6.6x Yoy